GIP and GLP-1 receptor co-agonist
VK2735 5.0 mg injection once weekly
VK2735_SC_5p0MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.58 (0.19 to 12.52) | 0.42 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 4.62 (0.79 to 34.07) | 0.29 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.57 (1.08 to 6.66) | 0.64 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.63 (1.18 to 34.19) | 0.40 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.85 (0.49 to 7.27) | 0.51 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.45 (0.70 to 8.77) | 0.42 |
| Overweight or obesity without diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 0.36 (0.00 to 12.81) | 0.73 |